基于鼻咽癌长期结局的质子脑特异性相对生物效应
PURPOSE: Uncertainties in relative biological effectiveness (RBE) constitute a major pitfall of the use of protons in clinics. An RBE value of 1.1, which is based on cell culture and animal models, is currently used in clinical proton planning.…
要点
- 质子治疗患者颞叶增强发生率为10%,调强放疗为4%。
- 质子治疗耐受剂量体积水平V10为26.1%,V20为21.9%,V30为14.0%,V40为7.7%,V50为4.8%,V60为3.3%(P < .03)。
- D1%耐受剂量质子为58.56 Gy,光子为69.07 Gy,计算得相对生物效应为1.18。
核心结论
- 基于鼻咽癌患者长期临床结局,质子治疗颞叶增强的相对生物效应在D1%处为1.18。
主要发现
- 质子治疗患者中10%出现单侧颞叶增强,调强放疗患者中为4%。
- 质子治疗耐受剂量体积水平分别为V10 26.1%、V20 21.9%、V30 14.0%、V40 7.7%、V50 4.8%、V60 3.3%(P < .03)。
- 质子治疗耐受剂量曲线在所有剂量水平均低于光子治疗,D1%耐受剂量质子为58.56 Gy,光子为69.07 Gy。
关键数值与推荐
- 晚期治疗效应定义为T1加权磁共振成像上颞叶增强,伴或不伴临床症状。
- 耐受剂量通过受试者工作特征分析和约登指数计算,耐受曲线以累积剂量体积直方图表示。
- 质子治疗颞叶增强的相对生物效应计算为1.18。
临床怎么用
- 临床质子计划中考虑脑组织相对生物效应可能高于1.1,尤其针对颞叶耐受剂量。
- 利用D1%耐受剂量58.56 Gy和相对生物效应1.18优化质子治疗计划以降低颞叶损伤风险。
局限性
- 需要大规模队列前瞻性研究证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Uncertainties in relative biological effectiveness (RBE) constitute a major pitfall of the use of protons in clinics. An RBE value of 1.1, which is based on cell culture and animal models, is currently used in clinical proton planning. The purpose of this study was to determine RBE for temporal lobe radiographic changes using long-term follow-up data from patients with nasopharyngeal carcinoma. METHODS AND MATERIALS: Five hundred sixty-six patients with newly diagnosed nasopharyngeal carcinoma received double-scattering proton therapy or intensity modulated radiation therapy at our institutions. The 2 treatment cohorts were well matched. Proton dose distributions were simulated using Monte Carlo and compared with those obtained from the proton clinical treatment planning system. Late treatment effect was defined as development of enhancement of temporal lobe on T1-weighted magnetic resonance imaging, with or without accompanying clinical symptoms. The tolerance dose was calculated with receiving operator characteristic analysis and the Youden index. Tolerance curves, expressed as a cumulative dose-volume histogram, were generated using the cutoff points. RESULTS: With a median follow-up period >5 years for both cohorts, 10% of proton patients and 4% of patients undergoing intensity modulated radiation therapy developed temporal lobe enhancement in unilateral temporal lobe. There was no significant difference in dose distributions between the Monte Carlo method and treatment planning system. The tolerance dose-volume levels were V10 (26.1%), V20 (21.9%), V30 (14.0%), V40 (7.7%), V50 (4.8%), and V60 (3.3%) for proton therapy (P < .03). Comparison of the two tolerance curves revealed that tolerance doses of proton treatments were lower than that of photon treatments at all dose levels. The dose tolerance at D1% was 58.56 Gy for protons and 69.07 Gy for photons. The RBE for temporal lobe enhancement from proton treatments were calculated to be 1.18. CONCLUSIONS: Using long-term clinical outcome of patients with nasopharyngeal carcinoma, our data suggest that the RBE for temporal lobe enhancement is 1.18 at D1%. A prospective study in a large cohort would be necessary to confirm these findings.
引用
- Zhang YY, Huo WL, Goldberg SI, et al. Brain-Specific Relative Biological Effectiveness of Protons Based on Long-term Outcome of Patients With Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2021. PMID: 33600889. doi:10.1016/j.ijrobp.2021.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。